Key Points from the Company Announcement

• Controlling Shareholder Acquisition: Tianjin Pharmaceutical Holdings Co., Ltd. (“TPH”), through its wholly-owned subsidiary JinYao Global Pte. Ltd., has increased its holding of S-Shares in Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.
• Recent Purchase Details: On 4 February 2026, JinYao Global acquired 82,200 S-Shares on the Singapore Exchange (SGX-ST) at an average price of US\$2.96 per share, totaling approximately US\$242,952.79. This represents about 0.0107% of the company’s total issued share capital.
• Shareholding Impact: TPH’s total shareholding increased from 331,120,528 shares (42.997% of the company) to 331,202,728 shares (43.008%). The S-Share portion rose from 5,265,000 to 5,347,200 shares.
• Proposed Further Shareholding Increase: JinYao Global plans to further increase its S-Share holdings within six months from the initial purchase date, not exceeding 1% of the company’s total issued share capital. Purchases will be made on the SGX-ST, with the price per share not surpassing US\$4, and the total consideration ranging between RMB14.3 million and RMB28.59 million.
• Funding: The acquisition was funded by JinYao Global’s internal resources.
• Lock-up Undertaking: JinYao Global has committed not to dispose of or reduce any of its existing shareholding in the company during the implementation period of the increase plan and within statutory periods as required by law.
• Risks and Uncertainties: The company notes that the proposed shareholding increase plan is subject to market conditions and other unforeseeable risks, which may impact its completion or effectiveness.
• No Change in Control: The shareholding increase will not affect the company’s listing status, public float requirements, or result in any change in control or controlling shareholder.
• Regulatory Compliance: The company will closely monitor the shareholding activities and ensure compliance with the Shanghai Stock Exchange and SGX-ST regulations, and will disclose material updates as necessary.

Implications for Shareholders & Investors

• Potentially Price Sensitive Event: The controlling shareholder’s move to increase its stake, alongside a formal plan to further boost shareholding, signals strong confidence in the company’s future and its investment value. Such actions by a major shareholder often imply positive expectations for the company’s prospects and can be interpreted as a bullish signal by the market.
• Potential Share Price Impact: The purchase price cap of US\$4 per S-Share is above the recent average acquisition price, suggesting the controlling shareholder sees further upside potential. The outlined price range and commitment not to sell shares could support share price stability or upward momentum.
• Risk Factors: Investors should be mindful that the shareholding increase plan is subject to market conditions and may not be fully implemented as intended. External factors could influence both the execution and the expected outcomes of the plan.
• No Dilution or Change in Control: The plan will not dilute existing shareholders or affect the company’s listing status or control structure, ensuring continuity and regulatory compliance.

Important Reminders

• Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares, especially in view of the ongoing shareholding increase plan and associated uncertainties.
• The company has undertaken to make timely disclosures of any further material developments.

Conclusion

The announcement of a shareholding increase by the controlling shareholder and a subsequent plan to acquire more S-Shares is a significant development that could influence investor sentiment and share price performance. The commitment and confidence demonstrated by the controlling shareholder, combined with a formal acquisition plan and lock-up undertaking, mark this as a potentially price-sensitive event for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. Share prices may be influenced by various factors, including market conditions and regulatory developments.

View TJ DaRenTang USD Historical chart here